Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.71 |
| ▸ | GSR | P00390 | 7/20 | 0.66 |
| ▸ | ACHE | P22303 | 4/20 | 0.58 |
| ▸ | USP2 | O75604 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CASP1 | P29466 | 2/20 | 0.58 |
| ▸ | CASP7 | P55210 | 2/20 | 0.58 |
| ▸ | HBB | P68871 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | PRNP | P04156 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18163884 | 0.99 | MBNL1 (0.74) | MBNL1MEN1KMT2ATDP1ADORA2A | |
| SCHEMBL8845400 | 0.99 | MBNL1 (0.74) | MBNL1MEN1KMT2ATDP1ADORA2A | |
| SCHEMBL7869225 | 0.95 | MBNL1 (0.81) | MBNL1MEN1KMT2ATDP1ADORA2A | |
| SCHEMBL20087053 | 0.94 | MBNL1 (0.80) | MBNL1MEN1KMT2ATDP1ADORA2A | |
| SCHEMBL20087077 | 0.94 | MBNL1 (0.80) | MBNL1MEN1KMT2ATDP1ADORA2A | |
| SCHEMBL20087027 | 0.94 | MBNL1 (0.80) | MBNL1MEN1KMT2ATDP1ADORA2A | |
| SCHEMBL22420450 | 0.93 | ADORA2A (0.72) | MBNL1MEN1KMT2ATDP1ADORA2A | |
| SCHEMBL22420449 | 0.93 | ADORA2A (0.74) | MBNL1MEN1KMT2ATDP1ADORA2A | |
| SCHEMBL7880398 | 0.93 | MEN1 (0.79) | MBNL1MEN1KMT2ATDP1ADORA2A | |
| SCHEMBL17423375 | 0.93 | MBNL1 (0.66) | MBNL1MEN1KMT2ATDP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019359-A1 | Antisense inhibition of angiogenin expression | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-02-14 | — | — | US | claimed |
| EP-0970102-A1 | ANTISENSE INHIBITION OF ANGIOGENIN EXPRESSION | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-01-12 | — | — | EP | claimed |
| WO-1998042722-A1 | ANTISENSE INHIBITION OF ANGIOGENIN EXPRESSION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-10-01 | — | — | WO | claimed |
| US-5135917-A | Bind to sense DNA strand coding for receptors | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-08-04 | — | — | US | claimed |
| WO-2023225631-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2022261296-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-15 | — | — | WO | disclosed |
| US-10774047-B2 | Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-09-15 | — | — | US | disclosed |
| WO-2017132420-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSION AND DIAGNOSIS OF CANCER METASTASIS | THE METHODIST HOSPITAL (US) | 2017-08-03 | — | — | WO | disclosed |
| US-9636354-B2 | Methods for sustained and regulatable gene expression using viral based expression vectors | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150231168-A1 | METHODS FOR SUSTAINED AND REGULATABLE GENE EXPRESSION USING VIRAL BASED EXPRESSION VECTORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-08-20 | — | — | US | disclosed |
| US-9023617-B2 | Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150005369-A1 | METHODS OF GENE DELIVERY USING CAPSID-MODIFIED RAAV EXPRESSION SYSTEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-01 | — | — | US | disclosed |
| WO-2000015783-A9 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO β1-ADRENOCEPTOR-SPECIFIC mRNA AND METHODS OF USE | UNIV FLORIDA (US) | 2000-08-24 | — | — | WO | disclosed |
| US-6087343-A | CONTROLLING HYPERTENSION AND CARDIOVASCULAR DISEASE FOR PROLONGED PERIODS WITH SINGLE DOSES | UNIVERSITY OF FLORIDA (US) | 2000-07-11 | — | — | US | disclosed |
| WO-2000015783-A2 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO β1-ADRENOCEPTOR-SPECIFIC mRNA AND METHODS OF USE | UNIVERSITY OF FLORIDA (US) | 2000-03-23 | — | — | WO | disclosed |
| EP-0970102-A1 | ANTISENSE INHIBITION OF ANGIOGENIN EXPRESSION | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999015643-A2 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | UNIVERSITY OF FLORIDA (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998042722-A1 | ANTISENSE INHIBITION OF ANGIOGENIN EXPRESSION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-10-01 | — | — | WO | disclosed |
| US-5135917-A | Bind to sense DNA strand coding for receptors | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-08-04 | — | — | US | disclosed |
| WO-1992000990-A1 | INTERLEUKIN RECEPTOR EXPRESSION INHIBITING ANTISENSE OLIGONUCLEOTIDES | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774047-B2 | Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy | ATG7, BECN1, SQSTM1 | MBNL1 3437/4885MEN1 3124/4885KMT2A 1608/4885 |
| US-20020019359-A1 | Antisense inhibition of angiogenin expression | TEK, RNASE1, RNGTT | MBNL1 72/4885MEN1 2575/4885KMT2A 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.